However, commercial implementation of this biomarker under the NEPHROCHECK© assay may constitute a positive sign for the broader adoption of TIMP2*IGFBP7 and other novel biomarkers of AKI for clinical use in the future. This evidence concerns the gene IGFBP7 and acute kidney injury.